ESMO TAT 2023 | JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines observations from the JAVELIN PARP Medley clinical trial (NCT03330405), a non-randomized controlled trial following on from pre-clinical evidence suggesting a synergistic effect when PARP inhibitors and immune checkpoint inhibitors are taken in combination. The study sought to discern which tumor types and molecular subtypes responded to this regime. 223 patients with advanced solid tumors were prescribed a combination of avelumab (a PDL-1 inhibitor) and talazoparib (a PARP inhibitor). While the response rates for combination therapy were comparable to the results of taking either therapeutic alone, the durability of the overall response rates was prolonged for patients with triple negative breast cancer (TNBC), HR+ breast cancer, HER2-negative breast cancer, DNA Damage Response (DDR)-positive breast cancer, and BRCA-mutated ovarian cancer. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.